Status: Recruiting
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Participants needed: 57
Trial details
Phase: Phase 2Age: 1-39Biological sex: AllType: InterventionalSponsor: Sabine Mueller, MD, PhDUpdated: Apr 23, 2026Locations: 20
Eligibility criteria
Newly diagnosed craniopharyngioma, as based on imaging characteristics and centr... [+30]
Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks f... [+12]